<?xml version="1.0" encoding="UTF-8"?>
<MedicinalProductClinicals xmlns="http://hl7.org/fhir">
  <id value="example"/>
  <undesirableEffects>
    <symptomConditionEffect>
      <coding>
        <system value="http://ema.europa.eu/example/undesirableeffectassymptom-condition-effect"/>
        <code value="Anaemia"/>
      </coding>
      <text value="Prevention of\nVTE in adult\npatients who have\nundergone\nelective hip or\nknee replacement\nsurgery (VTEp)"/>
    </symptomConditionEffect>
    <classification>
      <coding>
        <system value="http://ema.europa.eu/example/symptom-condition-effectclassification"/>
        <code value="Bloodandlymphaticsystemdisorders"/>
      </coding>
    </classification>
    <frequencyOfOccurrence>
      <coding>
        <system value="http://ema.europa.eu/example/frequencyofoccurrence"/>
        <code value="Common"/>
      </coding>
    </frequencyOfOccurrence>
  </undesirableEffects>
  <therapeuticIndication>
    <diseaseSymptomProcedure>
      <coding>
        <system value="http://ema.europa.eu/example/indicationasdisease-symptom-procedure"/>
        <code value="Venousthromboembolismprophylaxis"/>
      </coding>
      <text value="Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip\nor knee replacement surgery.\nPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation\n(NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age\n≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).\nTreatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent\nDVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients)."/>
    </diseaseSymptomProcedure>
    <comorbidity>
      <coding>
        <system value="http://ema.europa.eu/example/comorbidity"/>
        <code value="Hipsurgery"/>
      </coding>
    </comorbidity>
    <intendedEffect>
      <coding>
        <system value="http://ema.europa.eu/example/intendedeffect"/>
        <code value="PRYLX"/>
      </coding>
    </intendedEffect>
    <population>
      <ageRange>
        <low>
          <value value="18"/>
          <unit value="a"/>
        </low>
      </ageRange>
    </population>
  </therapeuticIndication>
  <contraindication>
    <disease>
      <coding>
        <system value="http://ema.europa.eu/example/contraindicationsasdisease-symptom-procedure"/>
        <code value="Coagulopathiesandbleedingdiatheses(exclthrombocytopenic)"/>
      </coding>
      <text value="Hepatic disease associated with coagulopathy and clinically relevant bleeding risk"/>
    </disease>
    <comorbidity>
      <coding>
        <system value="http://ema.europa.eu/example/comorbidity"/>
        <code value="Hepaticdisease"/>
      </coding>
    </comorbidity>
  </contraindication>
  <interactions>
    <interaction value="Inhibitors of CYP3A4 and P-gp\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\nequixaban Cmax.\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\nsection 4.4).\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp."/>
    <interactant>
      <coding>
        <system value="http://ema.europa.eu/example/interactant"/>
        <code value="ketoconazole"/>
      </coding>
    </interactant>
    <interactant>
      <coding>
        <system value="http://ema.europa.eu/example/interactant"/>
        <code value="itraconazole"/>
      </coding>
    </interactant>
    <type>
      <coding>
        <system value="http://ema.europa.eu/example/interactionsType"/>
        <code value="StrongInhibitorofCYP3A4"/>
      </coding>
    </type>
    <effect>
      <coding>
        <system value="http://ema.europa.eu/example/interactionseffect"/>
        <code value="Increasedplasmaconcentrations"/>
      </coding>
    </effect>
    <management>
      <coding>
        <system value="http://ema.europa.eu/example/managementactions"/>
        <code value="CoadministrationnotrecommendedinpatientsreceivingconcomitantsystemictreatmentstronginhibitorsofbothCYP3A4andP-gp"/>
      </coding>
    </management>
  </interactions>
</MedicinalProductClinicals>